公开(公告)号：US20220009933A1

公开(公告)日：2022-01-13

申请号：US17294705

申请日：2019-11-20

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Heeyeong Cho ,  Hee-Jong Lim ,  Woo Kyu Park ,  Dae Young Jeong ,  Hyeon Young Kim ,  Sae-Bom Yoon ,  Chong Ock Lee ,  Heung Kyoung Lee ,  Victor Sukbong HONG ,  Ji Hye Choi

IPC: C07D487/04 ,  C07D519/00 ,  C07D487/14 ,  A23L33/10

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases or tumors, containing, as an active ingredient, a tricyclic compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a health food composition for preventing or alleviating autoimmune diseases or tumors, containing the tricyclic compound as an active ingredient, wherein the tricyclic compound represented by Chemical Formula 1 has an excellent inhibitory activity against IRAK4, and thus can be usefully used for the prevention, treatment, or alleviation of autoimmune diseases or tumors.

公开(公告)号：US09650389B2

公开(公告)日：2017-05-16

申请号：US15029075

申请日：2014-12-30

Applicant: Korea Research Institute of Chemical Technology ,  The Catholic University of Korea Industry-Academic Cooperation Foundation

Inventor： Heeyeong Cho ,  Hee-Jong Lim ,  Ge Hyeong Lee ,  Woo Kyu Park ,  Hyeon Young Kim ,  Dae Young Jeong ,  Wan Uk Kim ,  Chul Soo Cho ,  Su Jung Park ,  Eun Jin Han

IPC: C07D491/153 ,  A61K31/4745

CPC classification number: C07D491/153 ,  A61K31/4745

Abstract: The preset invention relates to a novel 8-oxoprotoberberine derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases associated with the activity of NFAT5 containing the same as an active ingredient. The novel 8-oxoproteoberberine derivative or the pharmaceutically acceptable salt thereof according to the present invention can be useful in a pharmaceutical composition for preventing or treating diseases associated with the activity of NFAT5, particularly rheumatoid arthritis or inflammatory diseases, since it is ascertained that the derivative or a pharmaceutically acceptable salt thereof has remarkably increased oral absorption compared with known protoberberine due to an improvement in the properties thereof, and inhibits the activity of NFAT5 and the secretion of inflammatory cytokines and reduces the expression of NAFT5 in mice with rheumatoid arthritis by directly inhibiting the transcription of NFT5.